# Supplementary Online Content

Wiviott SD, Giugliano RP, Morrow DA, et al. Effect of evolocumab on type and size of subsequent myocardial infarction: a prespecified analysis of the FOURIER randomized clinical trial. *JAMA Cardiol*. Published online April 29, 2020. doi:10.1001/jamacardio.2020.0764

**eTable:** Baseline Characteristics by MI During Follow Up
**eFigure 1:** CONSORT Diagram
**eFigure 2:** KM Rates of MI Stratified by Universal MI Types
**eFigure 3:** Effect of Evolocumab by Month of Treatment

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable: Baseline Characteristics by MI During Follow Up

| FOURIER | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Baseline table, MI vs No MI during FU, ITT cohort** | | | | | | | |
| | MI during FU (%) | n | N | No MI during FU (%) | n | N | p-value |
| Male | 77.9 | 862 | 1107 | 75.3 | 19933 | 26457 | 0.056 |
| Caucasian | 87.4 | 968 | 1107 | 85.0 | 22490 | 26457 | 0.026 |
| Age >=75 years | 12.3 | 136 | 1107 | 9.0 | 2390 | 26457 | <0.001 |
| Age >=65 years | 46.3 | 513 | 1107 | 44.4 | 11741 | 26457 | 0.198 |
| LDL at final screening >=85 mg/dl | 69.9 | 774 | 1107 | 64.9 | 17176 | 26453 | <0.001 |
| Region | | | | | | | <0.001 |
| North America | 24.0 | 266 | 1107 | 16.3 | 4305 | 26457 | |
| Europe | 61.2 | 678 | 1107 | 63.0 | 16657 | 26457 | |
| Latin America | 4.2 | 47 | 1107 | 6.7 | 1776 | 26457 | |
| Asia | 10.5 | 116 | 1107 | 14.1 | 3719 | 26457 | |
| History of Prior MI | 89.8 | 994 | 1107 | 80.7 | 21357 | 26457 | <0.001 |
| History of Stroke | 15.8 | 175 | 1107 | 19.5 | 5162 | 26457 | 0.002 |
| History of PAD | 18.0 | 199 | 1107 | 13.0 | 3443 | 26457 | <0.001 |
| Time to prior MI <2 years | 45.7 | 454 | 993 | 37.3 | 7948 | 21327 | <0.001 |
| >=2 Prior MIs | 40.3 | 401 | 994 | 22.9 | 4884 | 21338 | <0.001 |
| Hx residual CAD with >= 40% stenosis in >=2 vessels | 30.4 | 336 | 1104 | 21.4 | 5671 | 26441 | <0.001 |
| History of TIA | 6.3 | 70 | 1107 | 5.4 | 1439 | 26449 | 0.206 |
| History of Hypertension | 82.7 | 916 | 1107 | 80.0 | 21168 | 26456 | 0.026 |
| History of Diabetes | 46.2 | 511 | 1107 | 36.2 | 9570 | 26457 | <0.001 |
| Current Smoker | 27.3 | 302 | 1107 | 28.3 | 7475 | 26455 | 0.480 |
| History CHF | 26.4 | 292 | 1107 | 23.1 | 6102 | 26457 | 0.010 |
| Prior coronary revasc | 78.0 | 862 | 1105 | 65.6 | 17331 | 26420 | <0.001 |
| Prior CABG | 29.7 | 328 | 1105 | 18.5 | 4898 | 26418 | <0.001 |
| History PCI | 66.7 | 737 | 1105 | 55.8 | 14736 | 26420 | <0.001 |

MI = myocardial infarction, FU = follow up n = number with a given characteristic, N = Number of subjects with or without MI, LDL = low density lipoprotein, PAD = peripheral artery disease, CAD = coronary artery disease, TIA = transient ischemic attack, CHF = congestive heart failure, CABG = coronary artery bypass grafting surgery, PCI = percutaneous coronary intervention

eFigure 1: CONSORT Diagram

**Randomized (n=27,564)**

**Randomized to Evolocumab (n=13,784)**
- Received at least 1 dose (n=13,769, >99%)
- Never received a dose (n=15)

**Randomized to Placebo (n=13,780)**
- Received at least 1 dose (n=13,756, >99%)
- Never received a dose (n=24)

**Premature permanent drug discontinuation (n=1682, 12%)**
- Due to adverse event (n=628)
- Due to patient request (n=786)
- Due to physician decision (n=34)
- Due to protocol specified criteria (n=14)
- Due to site closure/decision by sponsor (n=22)
- Other (n=198)

**Premature permanent drug discontinuation (n=1746, 13%)**
- Due to adverse event (n=581)
- Due to patient request (n=881)
- Due to physician decision (n=47)
- Due to protocol specified criteria (n=11)
- Due to site closure/decision by sponsor (n=37)
- Other (n=189)

**Died during follow up (n=444, 3.2%)**

**Withdrew Consent (n=88, 0.6%)**
- Vital status known (n=58)
- Vital status searched and not listed as dead in registry (n=3)
- Vital status unknown (n=27)

**Lost to Follow-up (n=5, <0.1%)**

**Died during follow up (n=426, 3.1%)**

**Withdrew Consent (n=105, 0.8%)**
- Vital status known (n=86)
- Vital status searched and not listed as dead in registry (n=1)
- Vital status unknown (n=18)

**Lost to Follow-up (n=13, <0.1%)**

**Included in Primary Efficacy Analysis (n=13,784)**

**Included in Primary Safety Analysis (n=13,769)**
- Excluded because never received study drug (n=15)

**Included in Primary Efficacy Analysis (n=13,780)**

**Included in Primary Safety Analysis (n=13,756)**
- Excluded because never received study drug (n=24)

eFigure 2: KM Rates of MI Stratified by Universal MI Types

eFigure 3: Effect of Evolocumab by month of treatment.



| | |
|---|---|
| Total | HR 0.73[0.65-0.82] |
| 0 to < 6 | HR 0.92 [0.74-1.16] |
| 6 to <12 | HR 0.69 [0.55-0.87] |
| 12 to <18 | HR 0.66 [0.51-0.85] |
| ≥ 18 | HR 0.65 [0.55-0.77] |

0.4      0.73      1.0      2.5